Tamoxifen, as a first-line endocrine therapy for ER/PR+ breast cancers, binds to the estrogen receptor to competitively block estrogen-induced target gene expression, which leads to suppression of cancer cell proliferation [50]. The gene discussed is ESR1; the disease is breast carcinoma.